Skip to content
  • Saturday, 15 August 2026
  • 12:14 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • UCLA Researchers Advance EGFR-Targeted Drug for Glioblastoma into Clinical Testing
Laboratory Automation & Robotics

UCLA Researchers Advance EGFR-Targeted Drug for Glioblastoma into Clinical Testing

Lana Keisha May 31, 2026 0

Los Angeles, CA – A novel drug candidate for glioblastoma, KTM-101, developed by researchers at the University of California, Los…

Read More
Laboratory Automation & Robotics

UCLA Researchers Advance EGFR-Targeted Drug for Glioblastoma into Clinical Testing

Lana Keisha May 20, 2026 0

Los Angeles, CA – In a significant development offering renewed hope in the challenging landscape of brain cancer treatment, researchers…

Read More
Laboratory Automation & Robotics

UCLA Researchers Advance EGFR-Targeted Drug for Glioblastoma into Clinical Testing

Lana Keisha May 13, 2026 0

In a significant stride forward against one of the most formidable and lethal human cancers, researchers at UCLA have successfully…

Read More
Laboratory Automation & Robotics

UCLA Researchers Advance EGFR-Targeted Drug for Glioblastoma into Clinical Testing

Lana Keisha May 5, 2026 0

Researchers at UCLA have achieved a significant milestone in the arduous fight against glioblastoma, a notoriously aggressive and lethal form…

Read More
McGill University Researchers Identify Specific Brain Cells Linked to Depression in Landmark StudyMolecular Switch Discovery Enhances Blood Stem Cell Activation for Improved Bone Marrow Transplants and Gene TherapiesTerray says TerraBind delivers 26x faster inference than Boltz-2 by skipping diffusion-based coordinate generationSustaining Surveillance Amidst CDC Testing Pause: Clinical Laboratories Step Up to Safeguard Public Health
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ